drug · small molecule
patient view →crizotinib
Marketedupdated 2mo agoby $PFE PFIZER INC🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and non-small cell lung carcinoma and 14 investigational indications.
indications
investigational
NSCLC
targets
EML4-ALKNPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor)ALK tyrosine kinase receptorHepatocyte growth factor receptorMacrophage-stimulating protein receptor
all catalysts(0)
nothing on the calendar yet
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that